Search

everythinglearnresearchcommunity

for

Search:↓

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Weekly bicalutamide is safe and effective, with 50 mg/week recommended.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

PRP and microneedling both effectively improve hair growth and thickness for treating hair loss.

Baricitinib was effective in treating alopecia areata in two major trials.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

STS01 1% effectively promotes hair regrowth with minimal side effects.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

5% minoxidil foam is effective and safe for hair regrowth in women with hair loss.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

A trial showed that a new treatment is safe and effective for male pattern baldness, with most participants growing new hair.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Guselkumab significantly improves psoriasis symptoms within 12 weeks.

The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.

Injections of special skin cells showed potential in treating hair loss, with some participants experiencing increased hair density.

The gene therapy showed significant wound healing and was safe for treating severe RDEB.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

3D imaging effectively tracks skin changes in vitiligo treatment.

CTP-543 is generally safe for treating alopecia areata.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.